AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
EMERYVILLE, Calif., Jan. 31, 2017 -- Amyris, Inc. (Nasdaq:AMRS) will report financial results for the fourth quarter and fiscal year ended December 31, 2016 after market close on Thursday, March 2, 2017.
The company will hold its quarterly conference call to discuss these results, as well as provide an update on the company's business and outlook, at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, March 2, 2017.
In addition, the company will provide details on March 2, 2017 regarding its plans to host an investor day showcasing its technology platform and commercial developments fueling growth in its business.
Conference Call:
Thursday, March 2, 2017, 4:30 p.m. ET/1:30 p.m. PT
Dial-in Number:
(866) 516-3867 (U.S. & International)
Access Code: 64316211
Audio Webcast:
A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: http://investors.amyris.com. A replay of the webcast will be available on the Investor Relations section of the Company's website approximately two hours after the conclusion of the call.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Amyris and the Amyris logo are registered trademarks of Amyris, Inc.
Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 [email protected] [email protected]
